|
In the present work mainly focused on the approach of the development of stability-indicating assay method for determination
of Rivaroxaban in tablet formulation. The RP-HPLC separation was carried out on Agilent HPLC 1200 series, Waters HPLC
with Empower software waters 2996 PDA, 2487, waters 2695 separation module PDA were used for quantitative estimation of
Rivaroxaban in pharmaceutical dosage form using a Purospher star RP18 end-capped, 5? Hiber (250×4.6mm) with mobile
phase comprising water: acetonitrile (60:40 v/v)+0.1 % TEA at flow rate of 1.0mL/min and UV detection at 280.0 nm. The
method was validated as per ICH guidelines for accuracy, precision, specificity, linearity and range, ruggedness and
robustness. The linearity of the proposed method was investigated in the range of 5% to 200% of the target concentration; the
correlation coefficient for Rivaroxaban was found to be 0.999 which indicates the linear relationship between detector
response and concentration. The proposed method was found to be simple, specific, linear and rugged and can be used for
routine quality control
|
